ArticleLiver cancer2025

Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study.

Jia-Yong Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.